Brought to you by 
Merck signs ADC deal with Sutro Biopharma
02 Feb 2023
Executive Summary
Sutro Biopharma Inc. (cancer antibodies) licensed Merck KGAA’s EMD Serono Inc. rights to develop and commercialize its antibody-drug conjugates (ADCs) against several undisclosed oncology targets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck signs ADC deal with Sutro Biopharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice